China

Next year will see plenty of deals in the biopharma space and a growing number of them will come from China, attendees at the Jefferies London Healthcare Conference heard.

As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.

The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.

China has proposed new guidelines designed to head off potential bribery by pharma companies related to the conduct of clinical studies and possible manipulation of outcomes.

While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.

LaNova Medicines, as well as other Chinese RNA interference specialists and developers of stem cell-based therapies, were among those securing new funds from venture capital and private equity firms over the past few months.

Direct seller's going to need more than larger number of distributors to generate sustainable growth, analysts say.

The exact causes leading to Chinese authorities’ investigation of the UK major remain unclear at this point, but its key oncology drugs are facing fierce local competition from homegrown rivals.